REG - James Halstead PLC - Trading Update

James HalsteadAnnouncement

30/01/2020 07:00

RNS Number : 2855B
James Halstead PLC
30 January 2020
 


 
 
30 January 2020
 
JAMES HALSTEAD PLC



Trading Update


James Halstead plc, the commercial flooring manufacturer and distributor, is providing the following trading update ahead of its interim results for the half-year to 31 December 2019.
 
In his AGM statement, on 6 December 2019, the Chairman, Mr. Anthony Wild, noted that trading to date had been encouraging in terms of turnover and profit for the first five months of the current financial year. This trend continued into December and, once again, the company expects to attain record turnover for the half-year. The projects supplied continue to span the globe with interesting examples such as the Hobbiton tourist resort in New Zealand and Agent Provocateur in London together with the ubiquitous supply of flooring to the NHS such as Chelsea & Westminster Hospital and Hull Royal Infirmary.
 
Turnover in the UK was 6.8% ahead of the prior year, a creditable performance against the prevailing market conditions. Underlying margins held up but in the period July through to September there were adverse manufacturing variances and incremental labour costs associated with extended shifts / overtime subsequent to a significant engineering breakdown. Notwithstanding this adversity the company expects to report record pre-tax profit for the half-year.
 
Our balance sheet remains robust.
 
Interim results will be published on 31 March 2020.
 



Enquiries:


















James Halstead plc


Tel: 0161 767 2500




Mark Halstead, Chief Executive








Gordon Oliver, Finance Director


















Hudson Sandler


Tel: 020 7796 4133




Nick Lyon /Nick Moore


















Panmure Gordon (Nomad and Joint Broker)


Tel: 020 7886 2500




Dominic Morley


















Arden Partners (Joint Broker)        
Richard Johnson
 


Tel: 020 7614 5900



 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTKKCBBCBKKKDB